Shell Asset Management Co. boosted its position in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 197.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,128 shares of the specialty pharmaceutical company’s stock after acquiring an additional 61,157 shares during the quarter. Shell Asset Management Co.’s holdings in Valeant Pharmaceuticals International were worth $13,407,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. NEXT Financial Group Inc increased its stake in Valeant Pharmaceuticals International by 6.2% in the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after acquiring an additional 600 shares during the last quarter. Financial Architects Inc increased its stake in Valeant Pharmaceuticals International by 10.5% in the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after acquiring an additional 1,000 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 2,763 shares during the last quarter. Cetera Investment Advisers acquired a new stake in Valeant Pharmaceuticals International in the second quarter valued at approximately $192,000. Finally, IPG Investment Advisors LLC acquired a new stake in Valeant Pharmaceuticals International in the second quarter valued at approximately $203,000. 50.44% of the stock is currently owned by institutional investors and hedge funds.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded down 2.64% during midday trading on Friday, reaching $12.15. 8,297,980 shares of the company’s stock traded hands. The stock’s market cap is $4.23 billion. Valeant Pharmaceuticals International, Inc. has a 52-week low of $8.31 and a 52-week high of $24.30. The company’s 50-day moving average price is $13.84 and its 200-day moving average price is $13.58.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The business had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.88) EPS. On average, equities analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

A number of brokerages have weighed in on VRX. Vetr upgraded shares of Valeant Pharmaceuticals International from a “buy” rating to a “strong-buy” rating and set a $14.26 target price on the stock in a research report on Thursday. Royal Bank Of Canada cut their target price on shares of Valeant Pharmaceuticals International from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research report on Friday. Canaccord Genuity set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Thursday, August 10th. Rodman & Renshaw restated a “neutral” rating and issued a $17.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Finally, Zacks Investment Research lowered shares of Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 13th. Five equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $17.56.

In related news, Director Schutter Richard U. De bought 10,000 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, with a total value of $143,300.00. Following the transaction, the director now owns 77,479 shares in the company, valued at approximately $1,110,274.07. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.87% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Position Lifted by Shell Asset Management Co.” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://theolympiareport.com/2017/10/20/valeant-pharmaceuticals-international-inc-vrx-position-lifted-by-shell-asset-management-co.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.